A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes
Latest Information Update: 12 May 2022
At a glance
- Drugs MK 8655 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 12 Dec 2012 Planned End Date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.